Nature Cancer

Article	Citations
Outcompeting neighbors for intestinal cancer initiation	508
Challenges and opportunities in training cancer researchers	332
Disparities in cancer treatments across ancestral backgrounds	322
Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity	317
Milestones in tumor vascularization and its therapeutic targeting	282
The never-abating excitement for targeted therapies	272
Targeting network circuitry in glioma	263
Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer	250
Five years of Nature Cancer	243
Breaking frontiers with multidisciplinary cancer research	241
Targeting T cell checkpoints and myeloid suppressor cells is effective in pancreatic cancer	232
CRC malignancy continuum	228
Circumventing the roadblocks to targeting EGFR-driven cancers	226
Untangling the threads of immunotherapy research	225
Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma	185
Diverse routes to melanoma metastasis and ICI resistance	183
Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers	181
The expanding success of T cell-engaging bispecific antibodies	174
KDM6B-mediated reprogramming of myeloid cells regulates the response to immunotherapy	172
Gut decisions in CAR T cell therapy	160
A low-coverage liquid biopsy for lung cancer	159
The expanding palette of immunotherapy research	153
Proteogenomic analysis of human pancreatic ductal adenocarcinoma	148
Master kinases extracted from proteogenomic networks in glioblastoma drive cancer subtypes	141
Cancer models for reverse and forward translation	138

Mitochondrial DNA mutation enhances sensitivity to immunotherapy in melanoma	135
An autologous antigen-agnostic dendritic cell therapy that forgoes antigen loading	132
Breaking the performance ceiling for neoantigen immunogenicity prediction	131
Outcomes of COVID-19 and risk factors in patients with cancer	122
A new sophistication for breast cancer PDXs	122
Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology	121
Ovarian cancer through a multi-modal lens	119
Author Correction: Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome	117
PARP11 interfer(on)es with CAR T cell efficacy	114
Enhancing childhood cancer targetability	111
SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers	110
Masking T cell engagers mitigates on-target off-tumor activity	102
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors	99
Harnessing immune checkpoint trial data in pediatric cancer	99
c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation	98
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells	97
Shooting for multiplexed pathology with Orion	97
Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab	97
Jeffrey W. Pollard (1950–2023)	96
Considering molecular alterations as pan-cancer tissue-agnostic targets	95
The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma	94
An oncolytic circular RNA therapy	93
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction	93
Endothelium directs fat remodeling in cachexia	92
Harnessing oncology real-world data with AI	89
Improving long-term outcomes in pediatric low-grade glioma	83
Enhanced precision in immunotherapy	82
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	82
Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer	81
Author Correction: Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical tri	81
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	81
Evolving cell states and oncogenic drivers during the progression of IDH-mutant gliomas	79
Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression	79
A platform for continuous learning in oncology	78
A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types	78
Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities	77
Author Correction: Sonic hedgehog accelerates DNA replication to cause replication stress promoting cancer initiation in medulloblastoma	75
2-HG modulates glioma macrophages via Trp metabolism	75
TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer	75
Chemotherapy induces canalization of cell state in childhood B-cell precursor acute lymphoblastic leukemia	73
Author Correction: Fatty acid synthesis is required for breast cancer brain metastasis	73
Alzheimer’s drug turns macrophages against cancer	72
Hitting the target in HER2 mutant cancers	71
Impaired immune responses in blood cancers improved by third COVID-19 vaccine dose	71
JAK inhibition shows two faces in prostate cancer	71
Author Correction: The immuno-oncological challenge of COVID-19	71
Two isoleucyl tRNAs that decode synonymous codons divergently regulate breast cancer metastatic growth by controlling translation of proliferation-regulating genes	70
Targeting both death and paracaspase domains of MALT1 with antisense oligonucleotides overcomes resistance to immune-checkpoint inhibitors	69
CAR T cell therapy: looking back and looking forward	69
Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers	68

Autotaxin–lysolipid signaling suppresses a CCL11–eosinophil axis to promote pancreatic cancer progression	68
PD-L2 expression in senescent cancer cells limits tumor clearance after chemotherapy	68
PRMT9 inhibition sparks immune responses in AML	67
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms	66
CD8+ T cell killing of MHC class I–deficient tumors	66
The moving target of cancer cell plasticity	65
Avoiding CAR-NK cell fratricide	65
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors	65
2022 through the eyes of the editors	64
The 2022 generation	63
Associations of seven measures of biological age acceleration with frailty and all-cause mortality among adult survivors of childhood cancer in the St. Jude Lifetime Cohort	63
TRIM28-dependent developmental heterogeneity determines cancer susceptibility through distinct epigenetic states	62
Immunological sex differences in glioblastoma	61
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment	61
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study	59
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis	59
Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumor immunity	58
Structural variants shape driver combinations and outcomes in pediatric high-grade glioma	58
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	58
Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation	57
γδ T cells as critical anti-tumor immune effectors	57
MALAT1 protects dormant tumor cells from immune elimination	57
METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma	56
Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting	56
Fatty acid synthesis is required for breast cancer brain metastasis	56
A single inhibitor for all KRAS mutations	55
The current landscape of immunotherapy for pediatric brain tumors	55
CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma	55
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	55
Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS	54
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma	54
Clinical and translational advances in ovarian cancer therapy	54
Microbiome dysbiosis, neutrophil recruitment and mesenchymal transition of mesothelial cells promotes peritoneal metastasis of colorectal cancer	54
FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy	54
Engineered bacteria for near-infrared light-inducible expression of cancer therapeutics	53
TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation	53
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	52
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	51
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer	51
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses	51
Overcoming therapy resistance in EGFR-mutant lung cancer	51
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial	50
Phosphate dysregulation via the XPR1–KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer	50
Publisher Correction: Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis	48
An antibody–toxin conjugate enhances innate immune cell responses in tumors	48
Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia	46
Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease	46
Centuries of genome instability and evolution in soft-shell clam, Mya arenaria, bivalve transmissible neoplasia	46
γδ T cell dichotomy with opposing cytotoxic and wound healing functions in human solid tumors	46
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	45
cfDNA methylome profiling for detection and subtyping of small cell lung cancers	45
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells	45
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	45
Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer	45
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer	45
Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment	44
Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity	44
A macrophage-activated abscopal effect	43
Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis	43
The cGAS–STING pathway and cancer	43
Leveraging translational insights toward precision medicine approaches for brain metastases	41
GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity	41
A PRC1–RNF2 knockout punch for cancer	41
The present and future of PI3K inhibitors for cancer therapy	41
The cornucopia of cancer biology	41
CD4+ T cells in cancer	41
Pulling the strings of tumor collagen	40
A needed boost against COVID-19 in lymphoma	40
An artificial intelligence framework integrating longitudinal electronic health records with real-world data enables continuous pan-cancer prognostication	40
Acute lymphoblastic leukemia displays a distinct highly methylated genome	40
Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy	39
Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction	39
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer	39
Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma	39
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor	38
Biocondensates fuel tumor immune evasion	38
Reaching your destination can require a diversion	37
Publisher Correction: Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: a multicenter prospective study	37
Publisher Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC	37
Publisher Correction: A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC	36

Neoadjuvant gemcitabine–cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial	36
Lung endothelium exploits susceptible tumor cell states to instruct metastatic latency	36
γδ T cells as unconventional targets of checkpoint blockade	36
Coming home to roost	36
Selenocysteine tRNA methylation promotes oxidative stress resistance in melanoma metastasis	35
Vascular heterogeneity of tight junction Claudins guides organotropic metastasis	35
Recapitulating the adenoma–carcinoma sequence by selection of four spontaneous oncogenic mutations in mismatch-repair-deficient human colon organoids	35
Inhibition of ERα signaling induces lineage plasticity in vivo	34
DePICting T cell–APC crosstalk in cancer	34
A multiverse of BRCA vulnerabilities	34
Bone marrow progenitor-like cells against leukemia cure	34
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial	33
Spatially resolved transcriptomics and graph-based deep learning improve accuracy of routine CNS tumor diagnostics	33
Finding the positive in triple-negative breast cancer	33
Fatty acid synthesis enables brain metastasis	33
Beating cancer one carbon at a time	32
High connectivity in gliomas affects cognition and survival	31
A dormancy mechanism limits metastasis of early spreading cancer cells	31
Communicating with respect	31
Leveraging the potential for deintensification in cancer care	31
Palmitoylation of GPX4 via the targetable ZDHHC8 determines ferroptosis sensitivity and antitumor immunity	30
Specific regulation of BACH1 by the hotspot mutant p53R175H reveals a distinct gain-of-function mechanism	30
Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)	30
Threonine fuels brain tumor growth through a conserved tRNA modification	29
Using machine learning to translate tumor dependencies	29
AI-assisted detection of lymph node metastases safely reduces costs and time	29
Palmitate oxidation drives a pro-metastatic post-translational modification	29
IKAROS and MENIN in synergy in AML	28
The year that was 2022	28
Defending health rights in a post-Roe world	28
Pediatric cancer incidence in China	28
The meaning of impact	28
Expanding the options for KRAS inhibition	28